摘要
2019年12月,一种新型冠状病毒肺炎(COVID-19)疫情在中国爆发,随后蔓延至全球,给全世界人民的生命安全及身体健康造成了严重的危害。2019-nCoV是一种RNA病毒,主要通过飞沫和接触传播,具有极强的传染性,准确、及时的诊断和鉴别诊断对于新型冠状病毒的感染控制及治疗至关重要。目前的COVID-19临床诊断项目主要包括新型冠状病毒核酸检测、人体免疫学检测及肺部影像学检测等,基于这些临床诊断项目,目前发展了一系列应用于COVID-19筛查、诊断、鉴别诊断及病毒变异监测的检测方法及技术。本文对这些COVID-19的诊断方法及技术原理、优劣势及临床适用场景进行了概述,并提出根据不同需要,将实验室指标与临床症状体征及影像检测有机结合,共同保证准确有效的诊断。
In December 2019,a new type of coronavirus pneumonia( COVID-19) broke out in China and then spread globally,causing serious harm to the lives and health of people around the world.2019-nCoV is an RNA virus that is mainly transmitted through droplets and contact.It is highly infectious,so accurate and timely diagnosis and differential diagnosis are essential for control of infection and treatment of COVID-19.Currently,clinical diagnosis projects of COVID-19 mainly include nucleic acid detection of novel coronavirus,human immunological detection and pulmonary imaging tests.Based on these clinical diagnosis projects,a series of detection methods and techniques have been developed for COVID-19 screening,diagnosis,differential diagnosis,and virus mutation monitoring. This review comprehensively made a summary on the principles,advantages,disadvantages,and clinical applicable scenarios of these diagnosis methods and techniques for COVID-19 and proposes to combine laboratory indicators with clinical symptoms and signs and image tests based on different needs to jointly guarantee accurate and effective diagnosis.
作者
陈红红
张行
顾月清
CHEN Hong-hong;ZHANG Hang;GU Yue-qing(School of Engineering,China Pharmaceutical University,Nanjing 211198,China)
出处
《药物生物技术》
CAS
2021年第1期88-93,共6页
Pharmaceutical Biotechnology
基金
国家自然科学基金(No.8172780057)
国家自然科学基金(No.8172900016)
国家自然科学基金(No.9185920071)。
